Logo
Saturday, June 13, 2026
The Cancer News

AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER

New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

January 1, 1970
New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

Categories

Cancer EducationPerspectivesHealth EquityHealth PolicyResources for Cancer PatientsResearch
More from Cancer Education
Mantle Cell Lymphoma in 2026: Auto-Transplant's Role Is fading, BTKi Combinations Are Frontline, and Brexu-cel Has Five-Year Data in RR-MCL

Mantle Cell Lymphoma in 2026: Auto-Transplant's Role Is fading, BTKi Combinations Are Frontline, and Brexu-cel Has Five-Year Data in RR-MCL

2026-06-09

HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line, Maintenance Gets Smarter, and Early Disease Is Changing Fast with TDxd neoadjuvant and adjuvant approvals

HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line, Maintenance Gets Smarter, and Early Disease Is Changing Fast with TDxd neoadjuvant and adjuvant approvals

2026-06-09

CAR-T Cell Therapy in Follicular Lymphoma and CLL: Identifying the High-Risk Patients Who Need It Most

CAR-T Cell Therapy in Follicular Lymphoma and CLL: Identifying the High-Risk Patients Who Need It Most

2026-05-25

The Hidden Barrier to Precision Oncology: How Insurance Policies Delay Access to Genomic Testing

The Hidden Barrier to Precision Oncology: How Insurance Policies Delay Access to Genomic Testing

2026-05-19

AI in Breast Diagnostics: Why What We Do With the Tool Matters More Than the Tool Itself

AI in Breast Diagnostics: Why What We Do With the Tool Matters More Than the Tool Itself

2026-05-18

Share Article

Get the Quick Bites delivered to your inbox daily